Product Description: Datopotamab (CDP7657) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan (HY-141598), TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan (HY-13631E) and Datopotamab[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Okajima D, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Dec;20(12):2329-2340.
CAS Number: 2267989-53-5
Molecular Weight: 145160
Compound Purity: 99.00
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: ADC Antibody;TROP2